Explore a selection of the 200+ articles we've published since our founding
Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer
Annals of Oncology (August 2017)Genomic changes that occur in breast cancer during the course of disease have been informed by sequencing of primary and metastatic tumor tissue. For patients with relapsed and metastatic disease, evolution of the breast cancer genome highlights the importance of using a recent sample for genomic profiling to guide clinical decision-making. Obtaining a metastatic tissue biopsy can be challenging, and analysis of circulating tumor DNA (ctDNA) from blood may provide a minimally invasive alternative.
Journal of Neuro-Oncology (2016)
Genomic research of high-grade glioma (HGG) has revealed complex biology with potential for therapeutic impact.
Molecular Cancer Therapeutics (August 2017)
Using retrospective analysis, this study found that patients with high tumor mutational burden (TMB) had better outcomes compared to patients with lower TMB.
Clinical Cancer Research (2017)
A prospective study of molecular profiling of tissue and blood in metastatic triple-negative breast cancer.
Patient-derived xenotransplants (PDX) can recapitulate the genetic driver landscape of acute leukemias
Leukemia (January 2017)
These data emphasize the importance of genomic profiling of PDX and patient samples to ensure concordance before performing mechanistic or therapeutic studies.
The Analytical Validation of a Hybrid Capture-based Next-generation Sequencing Clinical Assay for Genomic Profiling of Cell-free Circulating Tumor DNA
Journal of Molecular Diagnostics (June 2018)
An assay’s validation offers insight into the quality of its laboratory performance and its ability to confidently detect genomic variants at various frequency levels. In this validation study, 2,666 reference alterations were utilized to evaluate the FoundationACT liquid biopsy assay against multiple orthogonal methods, including matched tissue with FoundationOne®, achieving high sensitivity in detecting genomic alterations even at low mutant allele frequencies (MAF>0.25%) often observed in clinical samples.
Lung Cancer (September 2017)
This study demonstrates the importance of both tissue and blood based hybrid-capture based genomic profiling at disease progression to identifying novel resistance mechanisms in the clinic.
Next-Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients With Lymphoid Malignancies
JCO Precision Oncology (April 2017)
NGS identifies alterations that may be pharmacologically tractable in most patients with lymphoid malignancies, albeit with drugs that have usually been developed in the context of solid tumors.
Leukemia (June 2017)
In this study, the clinical utility of CGP to characterize previously undescribed activating fusion genes, in conjunction with childhood B- or T-ALL, and describe responses to TKIs is reported.
Journal of the National Comprehensive Cancer Network (February 2016)
This exceptional response to pazopanib treatment suggests that a subset of patients with angiosarcoma with genomic alterations in vascular signaling genes may respond well to pazopanib.